Kenya - English - Pharmacy and Poisons Board

yuria-pharm ltd. 10, amosova str. kyiv, ukraine - l-arginine aspartate - oral solution - 5 ml of solution contain 1 g of l-arginine… - other cardiac preparations

Kenya - English - Pharmacy and Poisons Board

yuria-pharm ltd. 10, amosova str. kyiv, ukraine - l-arginini hydrochloridum - solution for infusion - 1 ml contains 42 mg of arginine hydrochloride… - arginine hydrochloride

Kenya - English - Pharmacy and Poisons Board

yuria-pharm ltd. 10, amosova str. kyiv, ukraine - ofloxacin - solution for injection - 2mg/ml - ofloxacin

Kenya - English - Pharmacy and Poisons Board

yuria-pharm ltd 10 m. amosova str., p.o box 03680 kyiv - linezolid - solution for injection - 1 ml of solution contains 2 mg of linezolid (on… - linezolid

United States - English - NLM (National Library of Medicine)

orchid healthcare (a division of orchid chemicals & pharmaceuticals ltd.) - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - venlafaxine hydrochloride extended-release capsules is indicated for the treatment of major depressive disorder. the efficacy of venlafaxine hydrochloride extended-release capsules in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the dsm-iii-r or dsm-iv category of major depressive disorder (see clinical trials ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessne

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals, llc - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 30 mg in 1 ml - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). acute pain in adult patients ketorolac is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration, and adverse reactions ). patients should b

Kenya - English - Pharmacy and Poisons Board

yuria pharma ltd 108, verbovetskogo street, cherkassy, ukraine - fluconazole - solution for infusion - 2mg/ml - antimycotics for systemic use: triazolederivatives

Kenya - English - Pharmacy and Poisons Board

yuria pharma ltd 108, verbovetskogo street, cherkassy, ukraine - levofloxacin hemihydrate - solution for infusion - 5mg/ml - antibacterials for systemic use: fluoroquinolones

Kenya - English - Pharmacy and Poisons Board

yuria pharma ltd 108, verbovetskogo street, cherkassy, ukraine - paracetamol - solution for infusion - 10mg/ml - non-opioid analgesics andantipyretics: anilides

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: purified water; lactose monohydrate; titanium dioxide; isopropyl alcohol; pectin; magnesium stearate; triacetin; hyprolose; purified talc; mannitol; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.